• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy.

作者信息

Kleman Ariel, Singavi Arun, Pommert Lauren, Mathison Angela J, Hari Parameswaran, Dhakal Binod, Mohan Meera, Janz Siegfried, Knight Jennifer M, Shah Mithun V, Schinke Carolina, Burns Robert, Steinhardt George Francis, Rao Sridhar, Carlson Karen

机构信息

Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.

Virginia G. Piper Cancer Care Network, Scottsdale, AZ.

出版信息

Blood Adv. 2023 Sep 26;7(18):5549-5553. doi: 10.1182/bloodadvances.2022008953.

DOI:10.1182/bloodadvances.2022008953
PMID:36724511
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10514068/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f1/10514068/963c7c82b2a1/BLOODA_ADV-2022-008953-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f1/10514068/963c7c82b2a1/BLOODA_ADV-2022-008953-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f1/10514068/963c7c82b2a1/BLOODA_ADV-2022-008953-gr1.jpg

相似文献

1
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy.基因变异富集的时间线：从多发性骨髓瘤诊断到骨髓瘤相关髓系恶性肿瘤
Blood Adv. 2023 Sep 26;7(18):5549-5553. doi: 10.1182/bloodadvances.2022008953.
2
The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.二代测序在血细胞减少的骨髓瘤患者髓系肿瘤诊断中的应用
Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):e414-e426. doi: 10.1016/j.clml.2021.12.008. Epub 2021 Dec 11.
3
[Myeloproliferative masks of multiple myeloma: A review of literature and clinical case reports].
Ter Arkh. 2017;89(1):72-77. doi: 10.17116/terarkh201789172-77.
4
Myeloproliferative disorder during the course of multiple myeloma.
Acta Haematol. 1986;76(2-3):176-7. doi: 10.1159/000206048.
5
[Diagnosis versus differential diagnosis of multiple myeloma].[多发性骨髓瘤的诊断与鉴别诊断]
Vopr Onkol. 2004;50(4):406-16.
6
Case report of coexistence of myeloproliferative neoplasms and multiple myeloma.骨髓增殖性肿瘤与多发性骨髓瘤并存的病例报告。
Kaohsiung J Med Sci. 2020 Jun;36(6):469-470. doi: 10.1002/kjm2.12186. Epub 2020 Jan 31.
7
The simultaneous occurrence of multiple myeloma and JAK2 positive myeloproliferative neoplasms - Report on two cases.多发性骨髓瘤与JAK2阳性骨髓增殖性肿瘤同时发生——两例报告
J Med Life. 2015 Jan-Mar;8(1):55-61.
8
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.V617F JAK2突变在癌症及除经典骨髓增殖性疾病外的髓系恶性肿瘤中并不常见。
Blood. 2005 Oct 15;106(8):2920-1. doi: 10.1182/blood-2005-05-2087.
9
Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?骨髓增殖性肿瘤和多发性骨髓瘤是否具有相同的遗传易感性位点？
Int J Cancer. 2021 Apr 1;148(7):1616-1624. doi: 10.1002/ijc.33337. Epub 2020 Oct 27.
10
Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 (V617F) and JAK2 exon 12 allele burden disappearance during the follow-up of two patients.
Ann Hematol. 2016 Feb;95(3):529-31. doi: 10.1007/s00277-015-2559-9. Epub 2015 Nov 27.

引用本文的文献

1
Descriptive Characteristics of Multiple Myeloma Patients in King Abdulaziz Medical City National Guard.阿卜杜勒阿齐兹国王国民警卫队医疗城多发性骨髓瘤患者的描述性特征
Cureus. 2024 Jan 21;16(1):e52692. doi: 10.7759/cureus.52692. eCollection 2024 Jan.
2
Autologous transplant and second malignancies in MM.多发性骨髓瘤中的自体移植与第二原发性恶性肿瘤
Blood Adv. 2023 Jun 27;7(12):2731-2732. doi: 10.1182/bloodadvances.2023010051.

本文引用的文献

1
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.来那度胺可促进 TP53 突变的治疗相关髓系肿瘤的发展。
Blood. 2022 Oct 20;140(16):1753-1763. doi: 10.1182/blood.2021014956.
2
How I treat frontline transplantation-eligible multiple myeloma.我如何治疗一线适合移植的多发性骨髓瘤。
Blood. 2022 May 12;139(19):2882-2888. doi: 10.1182/blood.2020008735.
3
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.克隆性造血与接受移植的多发性骨髓瘤患者的不良结局相关。
Nat Commun. 2020 Jun 12;11(1):2996. doi: 10.1038/s41467-020-16805-5.
4
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias.骨髓瘤患者在继发性白血病发病前数年就可检测到干细胞突变。
Blood Adv. 2019 Dec 10;3(23):3962-3967. doi: 10.1182/bloodadvances.2019000731.
5
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.淋巴瘤自体干细胞移植后与不良预后相关的克隆性造血
J Clin Oncol. 2017 May 10;35(14):1598-1605. doi: 10.1200/JCO.2016.71.6712. Epub 2017 Jan 9.
6
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.来那度胺-地塞米松方案治疗复发/难治性多发性骨髓瘤患者期间的继发性原发性恶性肿瘤
Cancer Med. 2017 Jan;6(1):3-11. doi: 10.1002/cam4.799. Epub 2016 Nov 18.
7
Age-related clonal hematopoiesis associated with adverse outcomes.与不良预后相关的年龄相关性克隆性造血。
N Engl J Med. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26.
8
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.来那度胺与地塞米松长期治疗复发/难治性多发性骨髓瘤患者的疗效与安全性
Blood Cancer J. 2014 Nov 7;4(11):e257. doi: 10.1038/bcj.2014.77.
9
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.治疗相关性骨髓增生异常综合征和急性髓系白血病的突变分析。
Haematologica. 2013 Jun;98(6):908-12. doi: 10.3324/haematol.2012.076729. Epub 2013 Jan 24.
10
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.来那度胺治疗复发/难治性多发性骨髓瘤患者的第二原发性恶性肿瘤回顾。
Blood. 2012 Mar 22;119(12):2764-7. doi: 10.1182/blood-2011-08-373514. Epub 2012 Feb 9.